NCT03586518 Validating Novel, Non-contrast Cardiac MRI Imaging in Haemodialysis Patients
| NCT ID | NCT03586518 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Leicester |
| Condition | End Stage Kidney Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 9 participants |
| Start Date | 2019-11-03 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 9 participants in total. It began in 2019-11-03 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
There are currently no good ways of measuring levels of scarring in the hearts of patients with advanced kidney disease and patients on dialysis, although recent research has shown a new cardiac MRI technique, called native T1 mapping, may provide a solution to this. To assess the accuracy of this novel technique in dialysis patients, it is essential to undertake a study which compares native T1 mapping to actual levels of scarring in the hearts of patients on dialysis.
Eligibility Criteria
Inclusion Criteria: * Prevalent haemodialysis patient (more than 3 months) * Active on the supportive care register with anticipated death in the subsequent 12 months * Able to give informed consent * Consent to donation of heart for research following death * Able to understand written and verbal explanations in English Exclusion Criteria: * Contraindication to MRI scan (e.g. pacemaker, incompatible metallic implants, claustrophobia) * Patients with expected or potential infiltrative cardiomyopathy (e.g. amyloidosis) * Unable to give informed consent * Unable to understand written and verbal explanations in English
Contact & Investigator
James Burton, DM, FRCP
PRINCIPAL INVESTIGATOR
Associate Professor in Renal Medicine
Frequently Asked Questions
Who can join the NCT03586518 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying End Stage Kidney Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03586518 currently recruiting?
Yes, NCT03586518 is actively recruiting participants. Contact the research team at jb343@le.ac.uk for enrollment information.
Where is the NCT03586518 trial being conducted?
This trial is being conducted at Leicester, United Kingdom.
Who is sponsoring the NCT03586518 clinical trial?
NCT03586518 is sponsored by University of Leicester. The principal investigator is James Burton, DM, FRCP at Associate Professor in Renal Medicine. The trial plans to enroll 9 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.